A consultation process through the Scientific Advice procedure has commenced.
Our Research and Development Team has prepared questions regarding the production safety of a medicinal product for veterinary use based on allogeneic stem cells isolated from canine adipose tissue. The EMA opinion on the query will be presented this October at the earliest. Within the Scientific Advice procedure, the Company intends to validate the full pathway of safety studies, quality control studies and clinical trials of the product that are to allow for the successful regulatory approval thereof.